| |
| |
|
| Insider
Information: |
Harrison Seth Loring |
| Relationship: |
Director |
| City: |
Sydney, Nsw |
| State: |
C3 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
6 |
|
| Direct
Shares |
10,594,431 |
|
|
Indirect Shares
|
25,221,855 |
|
|
| Direct
Value |
$5,097,640 |
|
|
|
Indirect Value
|
$22,153,821 |
|
|
| Total
Shares |
35,816,286 |
|
|
| Total
Value |
$27,251,461 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
HeartWare International Inc |
HTWR |
Director |
2016-08-23 |
0 |
2016-08-23 |
0 |
Premium* |
|
|
Titan Pharmaceuticals Inc |
TTNP |
10% Owner |
2013-11-25 |
9,650,000 |
|
0 |
Premium* |
|
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
Director, 10% Owner |
2014-09-22 |
212,694 |
2014-09-22 |
7,912,079 |
Premium* |
|
|
Avalo Therapeutics, Inc |
AVTX |
Director, 10% Owner |
2015-10-20 |
595,436 |
2015-10-20 |
0 |
Premium* |
|
|
Stoke Therapeutics, Inc. |
STOK |
Director, 10% Owner |
2019-06-21 |
0 |
2020-11-24 |
17,161,713 |
Premium* |
|
|
Akero Therapeutics, Inc. |
AKRO |
Director |
2022-11-30 |
136,301 |
2022-11-30 |
148,063 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
89 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| HTWR |
HeartWare International I... |
Director |
– • – |
2012-12-12 |
4 |
S |
$81.82 |
$939,294 |
I/I |
(11,480) |
933,493 |
0 |
- |
|
| HTWR |
HeartWare International I... |
Director |
– • – |
2012-12-13 |
4 |
S |
$81.28 |
$8,825,061 |
I/I |
(108,571) |
824,922 |
0 |
- |
|
| HTWR |
HeartWare International I... |
Director |
– • – |
2012-12-14 |
4 |
S |
$81.01 |
$6,150,531 |
I/I |
(75,922) |
8,000 |
0 |
- |
|
| HTWR |
HeartWare International I... |
Director |
– • – |
2013-07-01 |
4 |
S |
$95.29 |
$1,253,734 |
D/D |
(13,118) |
140,302 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-10-25 |
4 |
S |
$44.92 |
$202,797 |
D/D |
(4,515) |
300,851 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-10-25 |
4 |
S |
$44.92 |
$220,359 |
I/I |
(4,906) |
326,813 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-10-26 |
4 |
S |
$43.08 |
$3,131,402 |
I/I |
(71,583) |
255,230 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-10-26 |
4 |
S |
$43.08 |
$2,882,142 |
D/D |
(65,885) |
234,966 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-10-27 |
4 |
S |
$41.12 |
$2,758,920 |
D/D |
(66,426) |
168,540 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-10-27 |
4 |
S |
$41.12 |
$2,997,575 |
I/I |
(72,172) |
183,058 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-10-28 |
4 |
S |
$40.28 |
$852,091 |
D/D |
(21,138) |
147,402 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-10-28 |
4 |
S |
$40.28 |
$925,738 |
I/I |
(22,965) |
160,093 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-11-30 |
4 |
S |
$46.44 |
$521,067 |
D/D |
(11,101) |
136,301 |
0 |
- |
|
| AKRO |
Akero Therapeutics, Inc. |
Director |
– • – |
2022-11-30 |
4 |
S |
$46.44 |
$564,673 |
I/I |
(12,030) |
148,063 |
0 |
- |
|
89 Records found
|
|
Page 4 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
